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Abstract

Methods

Onco-Hu Models: Humanized Mice for Evaluation of Immuno-Oncology Therapeutics. The Jackson Laboratory; 2019.

Fig.1. Humanized mouse models. NSG or NSG-SGM3 mice were engrafted
with HCB CD34+ HSC at 4-6-wks old. Mice were treated with sublethal
irradiation 4-6-hrs prior to receiving HCB CD34+ stem cells via IP injection.
The developing immune system was monitored via regular blood checks.
After 10-12-wks, tumors were started in the mammary fat pad of hu-mice.
The tumors were treated with NPS (1000, 100ns Blumlein line pulses at
50kV/cm and 3Hz) 16-20-weeks post-HCB CD34+ HSC engraftment.
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Treat human breast cancer tumors in humanized mice
Examine the NPS-induced immune response in humanized mice
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Fig.4. Human CD45+ leukocyte
expansion over time in HU-NSGM3
mice. Blood was collected from HUNSGM3 mice over the anticipated
engraftment timeframe. The first indication
of humanization is by observing the
percentage of human lymphocytes, which
are hCD45+ cells, in the blood. Here, you
can see that over time, only two of the mice
in this group developed human
lymphocytes, while the others rejected the
engrafted stem cells.
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Fig.5. Human lymphocyte populations in HU-NSGM3 mice after
humanization. Over time, the engrafted HCB CD34+ HSC expand and
differentiate into a variety of human immune cells, including B cells
(hCD19+), T cells (hCD3+), myeloid cells (hCD33+), and HSC (hCD38+).
However, adequate expansion rarely occurred, and data is shown for a single
mouse.
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▪ Inconsistent humanization
0

20

No. Days Post-Tx

Fig.3. Human PDX (A) and CDX (B) tumor volumes in HU-NSGM3 mice post-treatment with NPS.
Tumors were monitored for development and treated with NPS approximately 16-20-weeks post-engraftment
of HCB CD34+ HSC. (A) PDX tumors completely regressed after treatment; however, (B) CDX tumors
continued to develop after treatment. The progression of the CDX tumor development was the first time NPS
has been ineffective at inducing tumor death.
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▪ GvHD also occurred
▪ PDX tumors were often rejected
▪ PDX tumors were cleared with NPS
▪ CDX tumors did not regress with NPS

▪ Hu-mice that developed the human immune cells, rejected the PDX
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Fig.2. Representative analysis of HCB CD34+ stem cells pre-engraftment. The StemCell HCB CD34+ Stem
Cell Isolation Kit was used for positive selection of HCB CD34+ HSC. After cryopreservation, flow cytometry
was used to confirm the purity of the isolated cells prior to humanizing mice. Impure samples might include
various types of mature immune cells which could inadvertently induce graft-versus-host disease (GvHD) and
lead to premature mortality.
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Cancers are aggressive, evasive, and ruthless killers, claiming millions of
lives every year. Cancers are heterogeneous and there is often no single,
clearly defined problem as they harness and manipulate a multitude of
fundamental mechanisms at the very essence of life. To investigate these
mechanisms and vet potential interventive therapies, humanized mice offer a
unique model as a prelude to the use of nanosecond pulse stimulation (NPS), a
pulse power technology applying nanosecond duration, high electric field
pulses, to ablate human tumors. Immunodeficient mouse strains, NSG and
NSG-SGM3, were engrafted with human immune cells and human tumors,
which would allow us to study the effects of NPS therapy on the human tumor
and the human immune system, albeit not without trials and tribulations. Here
we show that mice engrafted with human cord blood CD34+ hematopoietic
stem cells (hCD34+ HSC) lack consistency in expansion and chimerism, or
variety of immune cell types. Unfortunately, mice that developed the human
immune system rejected the human tumors without treatment, while mice that
rejected the immune system developed the human tumors. Therefore, we had
mice with human immune systems and no tumor to treat, and mice with
tumors to treat yet no immune system to study. In non-humanized mice, NPS
induced complete tumor death in the patient derived mammary cancer
xenograft (PDX) model, but not in the MDA-MB-231 VIM-RFP mammary
cancer cell-derived xenograft (CDX) model. The absence of NPS elimination
of the CDX is the only known NPS cancer failure and requires further study.

Results

▪ Hu-mice that rejected the human immune cells, accepted the PDX
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